Abstracts tagged "polymyositis"

Abstract Number: 1058 • ACR Convergence 2020
The Relationship of Different Muscle Enzymes in Adult Myositis Patients
Rohit Aggarwal¹ and Tanya Chandra², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Connecticut, HARTFORD, CT
Background/Purpose: Muscle enzymes are a core set measure (CSM) in clinical trials. The 2016 ACR/EULAR myositis response criteria and the IMACS definition of improvement recommend…
Abstract Number: 119 • 2019 ACR/ARP Annual Meeting
Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model
Jeong Yeon Kim¹, Seon Uk Kim ², Ji soo Park ¹, Ji Hye Lee ³, Jae Hwan Shin ⁴, Do Wan Hwang ⁵, Yun Sang Lee ⁴, Jin Chul Paeng ⁴, Yong Soo Choi ⁶, Jung Wook hwang ⁷, Kyuboem Han ⁸, Chun Hyung Kim ⁸, Mi Jin Kim ⁸, Yeong-Wook Song ⁹ and Eun Young Lee ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Seoul, Republic of Korea, ⁴Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁵Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea, ⁶Department of Biotechnology, CHA University, Seongnam, Korea, Seongnam, Republic of Korea, ⁷Department of Biotechnology, CHA University, Seongnam, Korea., Seongnam, Republic of Korea, ⁸PAEAN Biotechnology Inc., Daejeon, Korea, Daejeon, Republic of Korea, ⁹Seoul National University Hospital, Seoul, Republic of Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Polymyositis is a chronic inflammatory myopathy associated with lymphocyte infiltration, especially CD8 + T cells to the muscle layer. C protein-induced myositis (CIM) is a murine…
Abstract Number: 122 • 2019 ACR/ARP Annual Meeting
Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis
Mari Kamiya¹, Kimito Kawahata ², Hitoshi Kohsaka ¹ and Fumitaka Mizoguchi ¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, Tokyo, Japan, ²Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In polymyositis (PM), CD8+ cytotoxic T lymphocytes (CTLs) are assumed to induce muscle cell death. We presumed that the injured muscle cells release pro-inflammatory…
Abstract Number: 740 • 2019 ACR/ARP Annual Meeting
Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease
Magdalena Benad ¹, Dirk Koschel ¹, Kristine Herrmann ¹, Kristin Wiefel ¹, Alexander Kleymann ¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: Interstitial lung disease (ILD) is a common and life-threatening organ manifestation of patients with various connective tissue diseases (CTDs), and with systemic sclerosis and…
Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Patompong Ungprasert¹, Wisit Cheungpasitporn ², Charat Thongprayoon ³, Karn Wijarnpreecha ⁴ and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²University of Mississippi Medical Center, Jackson, MS, ³Mayo Clinic Rochester, Rochester, MN, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…
Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Alain Sánchez-Rodríguez¹, Citlallyc Josefina Gómez-Ruiz ², Abril Montes-Yanes ² and Gabriel Medrano-Ramírez ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
Abstract Number: 1282 • 2019 ACR/ARP Annual Meeting
Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis
Prasanth Lingamaneni¹, Carrie Richardson ², Soumyasri Kambhatla ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago
Background/Purpose: Adults with polymyositis demonstrate wide variability in responses to treatment, and the risk factors for failure to achieve remission in polymyositis are largely unknown. …
Abstract Number: 1290 • 2019 ACR/ARP Annual Meeting
Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Iago Pinal-Fernandez¹, Maria Casal-Dominguez ¹, Assia Derfoul ¹, Katherine Pak ¹, Paul Plotz ¹, Frederick W. Miller ², Jose C Milisenda ³, Josep M Grau-Junyent ³, Albert Selva-O'Callaghan ⁴, Julie Paik ⁵, Jemima Albayda ⁶, Lisa Christopher-Stine ⁷, Thomas E Lloyd ⁵, Andrea M Corse ⁵ and Andrew L Mammen ¹, ¹National Institutes of Health, Bethesda, ²NIEHS, NIH, Bethesda, MD, ³Clinic Hospital, Barcelona, ⁴Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain, Barcelona, ⁵Johns Hopkins, Baltimore, ⁶Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis…
Abstract Number: 379 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
Julien Campagne¹, Thomas Moulinet², Jonathan Epstein³, Sabine Revuz⁴, Francois Maurier⁵, Marie-Hélène Schuhmacher⁶, Philippe Evon⁷, Alain Meyer⁸ and Roland Jaussaud², ¹Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, ²Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, ³Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ⁴Médecine Interne, Hôpitaux Privés de Metz, Metz, France, ⁵Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁶Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, ⁷Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, ⁸Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS),…
Abstract Number: 1210 • 2018 ACR/ARHP Annual Meeting
Sonographic Appearance of Inflammatory Myopathies: Increased Muscle Echointensity and Qualitative Changes
Kristofoor Leeuwenberg¹, Lisa Christopher-Stine¹, Clifton O. Bingham III², Julie J. Paik², Eleni Tiniakou³, Seth Billings⁴, Philippe Burlina⁴ and Jemima Albayda⁵, ¹Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University Applied Physics Lab, Laurel, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The use of ultrasound in the assessment of muscle conditions has grown over the years. Various myopathies have shown an increase in echo intensity…
Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Gihyun Myung¹, Winnie Nelson² and Maureen A. McMahon³, ¹Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, ²Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, ³University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…
Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Adam Schiffenbauer¹, Lisa G. Rider², Sara Faghihi-Kashani³, Komal Patel⁴ and Frederick W. Miller⁵, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].